Correlation Between Verrica Pharmaceuticals and CERo Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Verrica Pharmaceuticals and CERo Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Verrica Pharmaceuticals and CERo Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Verrica Pharmaceuticals and CERo Therapeutics Holdings, you can compare the effects of market volatilities on Verrica Pharmaceuticals and CERo Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Verrica Pharmaceuticals with a short position of CERo Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Verrica Pharmaceuticals and CERo Therapeutics.

Diversification Opportunities for Verrica Pharmaceuticals and CERo Therapeutics

-0.42
  Correlation Coefficient

Very good diversification

The 3 months correlation between Verrica and CERo is -0.42. Overlapping area represents the amount of risk that can be diversified away by holding Verrica Pharmaceuticals and CERo Therapeutics Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CERo Therapeutics and Verrica Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Verrica Pharmaceuticals are associated (or correlated) with CERo Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CERo Therapeutics has no effect on the direction of Verrica Pharmaceuticals i.e., Verrica Pharmaceuticals and CERo Therapeutics go up and down completely randomly.

Pair Corralation between Verrica Pharmaceuticals and CERo Therapeutics

Given the investment horizon of 90 days Verrica Pharmaceuticals is expected to under-perform the CERo Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Verrica Pharmaceuticals is 4.16 times less risky than CERo Therapeutics. The stock trades about -0.24 of its potential returns per unit of risk. The CERo Therapeutics Holdings is currently generating about -0.04 of returns per unit of risk over similar time horizon. If you would invest  2.31  in CERo Therapeutics Holdings on September 22, 2024 and sell it today you would lose (1.41) from holding CERo Therapeutics Holdings or give up 61.04% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Verrica Pharmaceuticals  vs.  CERo Therapeutics Holdings

 Performance 
       Timeline  
Verrica Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Verrica Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's fundamental indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
CERo Therapeutics 

Risk-Adjusted Performance

10 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in CERo Therapeutics Holdings are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, CERo Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Verrica Pharmaceuticals and CERo Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Verrica Pharmaceuticals and CERo Therapeutics

The main advantage of trading using opposite Verrica Pharmaceuticals and CERo Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Verrica Pharmaceuticals position performs unexpectedly, CERo Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CERo Therapeutics will offset losses from the drop in CERo Therapeutics' long position.
The idea behind Verrica Pharmaceuticals and CERo Therapeutics Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Other Complementary Tools

Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance